GTCR Completes Acquisition of Zentiva From Advent to Expand European Generics Platform

September 11, 2025

GTCR has completed its previously announced acquisition of Zentiva, a leading European generics pharmaceutical company, from Advent. The deal expands GTCR’s European generics healthcare platform and is intended to drive growth through continued investment in product development, portfolio breadth, and geographic reach.

Buyers
GTCR, GTCR (as acquiring entity)
Targets
Zentiva
Sellers
Advent International
Industry
Pharmaceuticals
Location
Czech Republic
Transaction Type
Buyout

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.